{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:27Z","timestamp":1793316327352,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10147-018-1259-6","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T04:17:37Z","timestamp":1520396257000},"page":"410-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-2647","authenticated-orcid":false,"given":"Hiroki","family":"Nagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"1259_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480\u2013489","journal-title":"Nature"},{"issue":"8","key":"1259_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"4","key":"1259_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330","journal-title":"N Engl J Med"},{"issue":"1","key":"1259_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334","journal-title":"N Engl J Med"},{"issue":"2","key":"1259_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"issue":"17","key":"1259_CR6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"issue":"25","key":"1259_CR7","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376(25):2415\u20132426","journal-title":"N Engl J Med"},{"issue":"19","key":"1259_CR8","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"},{"key":"1259_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255\u2013265","journal-title":"Lancet"},{"issue":"19","key":"1259_CR10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813","journal-title":"N Engl J Med"},{"key":"1259_CR11","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283\u20131294","journal-title":"Lancet Oncol"},{"key":"1259_CR12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909\u20131920","journal-title":"Lancet"},{"issue":"11","key":"1259_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026","journal-title":"N Engl J Med"},{"issue":"19","key":"1259_CR14","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867","journal-title":"N Engl J Med"},{"issue":"10111","key":"1259_CR15","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461\u20132471","journal-title":"Lancet"},{"key":"1259_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1634\/theoncologist.13-S4-2","volume":"13","author":"JD Wolchok","year":"2008","unstructured":"Wolchok JD, Saenger Y (2008) The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13:2\u20139","journal-title":"Oncologist"},{"issue":"3","key":"1259_CR17","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","volume":"69","author":"K Minkis","year":"2013","unstructured":"Minkis K, Garden BC, Wu S et al (2013) The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 69(3):e121\u2013e128","journal-title":"J Am Acad Dermatol"},{"key":"1259_CR18","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.2217\/fon.15.118","volume":"11","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, El Halawani H, Fouad M (2015) Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol 11:2471\u20132484","journal-title":"Future Oncol"},{"issue":"4","key":"1259_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jgh.12888","volume":"30","author":"R Cheng","year":"2015","unstructured":"Cheng R, Cooper A, Kench J et al (2015) Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 30(4):657\u2013666","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"1259_CR20","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","volume":"58","author":"AM Giacomo Di","year":"2009","unstructured":"Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58(8):1297\u20131306","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"1259_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.mayocp.2013.01.015","volume":"88","author":"NM Gentile","year":"2013","unstructured":"Gentile NM, D\u2019Souza A, Fujii LL et al (2013) Association between ipilimumab and celiac disease. Mayo Clin Proc 88(4):414\u2013417","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1259_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA et al (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21(2):371\u2013381","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"1259_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-14-0845","volume":"172","author":"F Albarel","year":"2015","unstructured":"Albarel F, Gaudy C, Castinetti F et al (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172(2):195\u2013204","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1259_CR24","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.2337\/dc15-1331","volume":"38","author":"C Gaudy","year":"2015","unstructured":"Gaudy C, Cl\u00e9vy C, Monestier S et al (2015) Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 38(11):e182\u2013e183","journal-title":"Diabetes Care"},{"issue":"3","key":"1259_CR25","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1378\/chest.12-1467","volume":"143","author":"IZ Barjaktarevic","year":"2013","unstructured":"Barjaktarevic IZ, Qadir N, Suri A et al (2013) Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143(3):858\u2013861","journal-title":"Chest"},{"issue":"17","key":"1259_CR26","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","volume":"30","author":"G Berthod","year":"2012","unstructured":"Berthod G, Lazor R, Letovanec I et al (2012) Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 30(17):e156\u2013e159","journal-title":"J Clin Oncol"},{"issue":"2","key":"1259_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0000000000000070","volume":"38","author":"I Thaipisuttikul","year":"2015","unstructured":"Thaipisuttikul I, Chapman P, Avila EK (2015) Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother 38(2):77\u201379","journal-title":"J Immunother"},{"issue":"1","key":"1259_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","volume":"36","author":"C Gaudy-Marqueste","year":"2013","unstructured":"Gaudy-Marqueste C, Monestier S, Franques J et al (2013) A severe case of ipilimumab-induced Guillain\u2013Barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36(1):77\u201378","journal-title":"J Immunother"},{"issue":"2","key":"1259_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mus.24648","volume":"52","author":"AI Loochtan","year":"2015","unstructured":"Loochtan AI, Nickolich MS, Hobson-Webb LD (2015) Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52(2):307\u2013308","journal-title":"Muscle Nerve"},{"issue":"1","key":"1259_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/CMR.0b013e32835c7e68","volume":"23","author":"SG Bernardo","year":"2013","unstructured":"Bernardo SG, Moskalenko M, Pan M et al (2013) Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 23(1):47\u201354","journal-title":"Melanoma Res"},{"issue":"8","key":"1259_CR31","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Berman D (2012) Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 57(8):2233\u20132240","journal-title":"Dig Dis Sci"},{"issue":"33","key":"1259_CR32","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1200\/JCO.2011.41.4359","volume":"30","author":"C Voskens","year":"2012","unstructured":"Voskens C, Cavallaro A, Erdmann M et al (2012) Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 30(33):e356\u2013e357","journal-title":"J Clin Oncol"},{"issue":"2","key":"1259_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"F Fadel","year":"2009","unstructured":"Fadel F, Karoui EIK, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361(2):211\u2013212","journal-title":"N Engl J Med"},{"issue":"4","key":"1259_CR34","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","volume":"32","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Gueutin V, Gharbi C et al (2014) Kidney injuries related to ipilimumab. Invest New Drugs 32(4):769\u2013773","journal-title":"Invest New Drugs"},{"issue":"2","key":"1259_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1078155211411001","volume":"18","author":"S Ahmad","year":"2012","unstructured":"Ahmad S, Lewis M, Corrie P et al (2012) Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J Oncol Pharm Pract 18(2):287\u2013292","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"1259_CR36","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","volume":"32","author":"M Akhtari","year":"2009","unstructured":"Akhtari M, Waller EK, Jaye DL et al (2009) Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 32(3):322\u2013324","journal-title":"J Immunother"},{"issue":"6","key":"1259_CR37","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/CJI.0000000000000041","volume":"37","author":"P Rusquec Du","year":"2014","unstructured":"Du Rusquec P, Saint-Jean M, Brocard A et al (2014) Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother 37(6):348\u2013350","journal-title":"J Immunother"},{"issue":"1","key":"1259_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","volume":"38","author":"MMK Chan","year":"2015","unstructured":"Chan MMK, Kefford RF, Carlino M et al (2015) Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 38(1):37\u201339","journal-title":"J Immunother"},{"issue":"4","key":"1259_CR39","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1017\/S0317167100007939","volume":"36","author":"G Hunter","year":"2009","unstructured":"Hunter G, Voll C, Robinson CA (2009) Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 36(4):518\u2013520","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"1259_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","volume":"3","author":"H L\u00e4ubli","year":"2015","unstructured":"L\u00e4ubli H, Balmelli C, Bossard M et al (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3(1):11","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1259_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","volume":"3","author":"BP Geisler","year":"2015","unstructured":"Geisler BP, Raad RA, Esaian D et al (2015) Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 3(1):4","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1259_CR42","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.jcjo.2014.10.010","volume":"50","author":"E Miserocchi","year":"2015","unstructured":"Miserocchi E, Cimminiello C, Mazzola M et al (2015) New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol 50(1):e2\u2013e4","journal-title":"Can J Ophthalmol"},{"issue":"7","key":"1259_CR43","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35(7):785\u2013792","journal-title":"J Clin Oncol"},{"issue":"2","key":"1259_CR44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","volume":"152","author":"M Khunger","year":"2017","unstructured":"Khunger M, Rakshit S, Pasupuleti V et al (2017) Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 152(2):271\u2013281","journal-title":"Chest"},{"issue":"2","key":"1259_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cncr.31043","volume":"124","author":"RN Pillai","year":"2018","unstructured":"Pillai RN, Behera M, Owonikoko TK et al (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer 124(2):271\u2013277","journal-title":"Cancer"},{"issue":"2","key":"1259_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155\u2013164","journal-title":"Lancet Oncol"},{"key":"1259_CR47","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372\u20138377","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1259_CR48","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886\u2013894","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1259_CR49","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559\u2013574","journal-title":"Ann Oncol"},{"key":"1259_CR50","unstructured":"Bristol-Meyers Squibb: Yervoy (ipilimumab): Immune-mediated adverse reaction management guide. \n                    http:\/\/www.hcp.yervoy.com\/servlet\/servlet.FileDownload?file=00Pi000000PI1ZVEA1\n                    \n                  . Accessed 6 Mar 2018"},{"issue":"28","key":"1259_CR51","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang T-O et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 33(28):3193\u20133198","journal-title":"J Clin Oncol"},{"issue":"21","key":"1259_CR52","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691\u20132697","journal-title":"J Clin Oncol"},{"issue":"9","key":"1259_CR53","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/cncr.27969","volume":"119","author":"JS Weber","year":"2013","unstructured":"Weber JS, Dummer R, de Pril V et al (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119(9):1675\u20131682","journal-title":"Cancer"},{"issue":"3","key":"1259_CR54","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/eci.12410","volume":"45","author":"A Kronbichler","year":"2015","unstructured":"Kronbichler A, Jayne DRW, Mayer G (2015) Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 45(3):346\u2013368","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"1259_CR55","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00262-014-1607-y","volume":"63","author":"M Pedersen","year":"2014","unstructured":"Pedersen M, Andersen R, N\u00f8rgaard P et al (2014) Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother 63(12):1341\u20131346","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1259_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40425-014-0035-z","volume":"2","author":"C Kyi","year":"2014","unstructured":"Kyi C, Carvajal RD, Wolchok JD et al (2014) Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2(1):35","journal-title":"J Immunother Cancer"},{"key":"1259_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40425-015-0064-2","volume":"3","author":"AD Bostwick","year":"2015","unstructured":"Bostwick AD, Salama AK, Hanks BA (2015) Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer 3:19","journal-title":"J Immunother Cancer"},{"key":"1259_CR58","doi-asserted-by":"publisher","unstructured":"Weinstock C, Singh H, Maher VE et al (2017) FDA analysis of patients with baseline autoimmune diseases treated with PD-1\/PD-L1 immunotherapy agents. J Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.3018","DOI":"10.1200\/JCO.2017.35.15_suppl.3018"},{"key":"1259_CR59","doi-asserted-by":"publisher","unstructured":"Leonardi GC, Gainor JF, Azimi RS et al (2017) Use of PD-1 pathway inhibitors among patients with non-small cell lung cancer (NSCLC) and preexisting autoimmune disorders. J Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9081","DOI":"10.1200\/JCO.2017.35.15_suppl.9081"},{"key":"1259_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos FX, Voisin AL, Dyevre V et al (2018) Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 91:21\u201329","journal-title":"Eur J Cancer."},{"key":"1259_CR61","doi-asserted-by":"publisher","unstructured":"Santini FC, Rizvi H, Wilkins O et al (2017) Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9012","DOI":"10.1200\/JCO.2017.35.15_suppl.9012"},{"issue":"1","key":"1259_CR62","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack MH, Betof A, Dearden H et al (2018) Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29(1):250\u2013255","journal-title":"Ann Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1259-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1259-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1259-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T20:33:44Z","timestamp":1551904424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1259-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1259-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"23 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Complaince with ethical standards"}},{"value":"None of the authors of this study declared conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}